ghk cu copd NL-GHK-Cu in lung diseases – Synthagen PL GHK-CU

The keap1-nrf2 pathway: Promising therapeutic target to counteract ros-mediated damage in cancers and neurodegenerative diseases

EFFECT A NEW STANDARD IN PEPTIDE TECHNOLOGY By combining two patented innovations NL-PEPTIDES and NL-PEPTIDES-DELIVERY we created a system that solves three fundamental challenges in modern peptide pharmacology: Stability resistance to external factors and digestive enzymes

GHK-Cu is not an FDA-approved pharmaceutical

All bones were checked in dependence of different moments of bending (one point bending) (moment of bending = Nm) in different directions, anterior- posterior-, and latero-lateral